Brought to you by 
Caris Life Sciences gets $150mm through debt/notes deal with TPG; $75M added
22 Apr 2022
Executive Summary
TPG Sixth Street Partners invested $150mm in growth capital into cancer profiling firm Caris Life Sciences through the purchase of senior secured debt and convertible notes. The funding is the first time Caris has received external money since the company was formed in 2008.
Deal Industry
- Biotechnology
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Digital Health
- Artificial Intelligence
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Caris Life Sciences gets $150mm through debt/notes deal with TPG; $75M added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice